Stay updated on Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.5, and the previous version 2.16.4 has been removed. Additionally, information regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    0.7%
    Check dated 2025-07-04T04:04:52.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    22 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.5%
    Check dated 2025-06-19T19:36:38.000Z thumbnail image
  4. Check
    29 days ago
    No Change Detected
  5. Check
    36 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.0%
    Check dated 2025-06-05T11:10:59.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    The web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    0.9%
    Check dated 2025-05-29T05:57:31.000Z thumbnail image
  7. Check
    72 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.0%
    Check dated 2025-04-30T13:56:20.000Z thumbnail image
  8. Check
    86 days ago
    Change Detected
    Summary
    The webpage has undergone significant updates, including the removal of detailed information about a proposed phase I/II study involving cabozantinib for treating relapsed/refractory multiple myeloma, while adding references to collaborators and a new version revision.
    Difference
    61%
    Check dated 2025-04-16T02:02:53.000Z thumbnail image

Stay in the know with updates to Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib Reverses Carfilzomib Resistance in Myeloma Clinical Trial page.